AL Amyloidosis market size in the seven major markets was USD 920 million in 2021

The AL Amyloidosis Market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.

The AL Amyloidosis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted AL Amyloidosis symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current AL Amyloidosis symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Key takeaways from the AL Amyloidosis Market Research Report
• The total number of Incident cases of AL Amyloidosis associated in 7MM countries was approximately 8,600 in 2021.
• According to DelveInsight, the AL Amyloidosis market in 7MM is expected to grow steadily during the study period 2019-2032.
• AL Amyloidosis Market Companies are working such as Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, and others.
• AL Amyloidosis Pipeline therapies such as CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, NEOD001, Siltuximab, NEOD001, Lenalidomide, Melphalan, and others.

Recent Developmental Activities in the AL Amyloidosis Market

In January 2021, Janssen Biotech announced that the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain (AL) amyloidosis. Janssen Biotech announced updated positive results from the Phase III ANDROMEDA study, which is evaluating daratumumab and hyaluronidase-fihj for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys, and liver. Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) compared to VCd alone.

Birtamimab has been tested in nearly 300 patients with AL amyloidosis at the intended clinical dose of 24 mg/kg and was shown to be generally safe and well-tolerated in the clinical studies conducted to date. Birtamimab was previously evaluated in Phase III VITAL Study, a global multi-center, randomized, double-blind, placebo-controlled clinical study of newly diagnosed, treatment naïve patients with AL amyloidosis and cardiac involvement. Results from the analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study revealed a significant survival benefit favoring birtamimab in these patients, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the control group.

Discover which therapies are expected to grab the major AL Amyloidosis market share @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

AL Amyloidosis Overview

Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. It starts in the bone marrow, the soft tissue inside the bones that makes blood-forming cells, including cells that create antibodies to fight infections. These cells can grow abnormally, causing an excess type of protein called light chains, which clump together and form amyloid deposits in major organs. Progressive organ dysfunction (Heart, Kidney, Liver, etc.) is driven by amyloid deposition, and the risk of early death is the hallmark of severe AL amyloidosis.

AL Amyloidosis Epidemiology Segmentation in the 7MM
• Total AL Amyloidosis Incident cases
• AL Amyloidosis Gender-specific cases
• AL Amyloidosis Age-specific cases

Download the report to understand which factors are driving AL amyloidosis epidemiology trends @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

AL Amyloidosis Emerging Drugs

Daratumumab: Janssen Pharmaceutical/Genmab

Daratumumab (Darzalex Faspro) is an IgG1k monoclonal antibody, first-CD38 directed targeted therapy, and binds to CD38. Daratumumab binds to a different CD38 epitope amino-acid sequence than causing cell apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis. These effects are dependent upon fragment crystallizable region immune effector mechanisms. Antibody-dependent cellular cytotoxicity utilizes natural killer cells.

Birtamimab: Prothena

Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.

AL Amyloidosis Treatment Market

AL Amyloidosis treatment is highly individualized, determined based on age, the severity of organ damage/dysfunction, co-morbidities, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in almost two-thirds of patients. Novel agents are also active, and trials are ongoing to establish their optimal use. Currently, the Bortezomib-based regimen (CyBorD-cyclophosphamide, bortezomib, and dexamethasone) are currently used as first-line therapy in AL amyloidosis. The CyBorD regimens are in wide use in the US, EU, and Japan. Oral melphalan 1 dexamethasone (MDex) has been a standard of care for many years in treating relapsing and refractory patients. Daratumumab plus hyaluronidase (Darzalex Faspro) in combination with bortezomib, cyclophosphamide, and dexamethasone has been granted accelerated approval, for newly diagnosed light chain (AL) amyloidosis, by US FDA, in January 2021. It is likely to become the next Standard of Care for AL Amyloidosis in the 7MM.

To know more about AL Amyloidosis Clinical Trials, visit @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Al Amyloidosis Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period-2022-2032
• AL Amyloidosis Market Companies - Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, and others.
• AL Amyloidosis Pipeline therapies -101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, NEOD001, Siltuximab, NEOD001, Lenalidomide, Melphalan, and others.
• AL Amyloidosis Market Drivers, Barriers, Access, Unmet Needs

Table of Content
1. Key Insights
2. AL Amyloidosis Market Report Introduction
3. AL Amyloidosis Market Overview at a Glance
4. AL Amyloidosis Executive Summary
5. AL Amyloidosis Disease Background and Overview
6. AL Amyloidosis Epidemiology and Patient Population
7. AL Amyloidosis Patient Journey
8. AL Amyloidosis Emerging Therapies
9. Other Promising Therapies
10. AL Amyloidosis: 7 Major Market Analysis
11. AL Amyloidosis SWOT Analysis
12. AL Amyloidosis Unmet Needs
13. KOL Views
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

Learn more about the AL Amyloidosis Market Drivers & Barriers @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight
Contact Person: Yash
Email: pmaurya@delveinsight.com
Phone: +919650213330
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.